DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low risk0–0
  • Intermediate-1 risk1–2
  • Intermediate-2 risk3–4
  • High risk5–8
Direct Clinical Answer

The DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include scoring system. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Estimates survival in patients with primary myelofibrosis using clinical and laboratory parameters

Clinical Indication

The DIPSS/DIPSS Plus (Dynamic International Prognostic Scoring System) for Myelofibrosis is indicated for bedside clinical practice to support Estimates survival in patients with primary myelofibrosis using clinical and laboratory parameters. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.

Formula & Variables:

DIPSS Score: Age >65 (1 point) + WBC >25,000/μL (1 point) + Hemoglobin <10 g/dL (2 points) + Peripheral blast ≥1% (1 point) + Constitutional symptoms (1 point). DIPSS Plus adds: Unfavorable karyotype (1 point) + Platelets <100,000/μL (1 point) + Transfusion dependency (1 point).

Input Parameters

NameTypeRequiredDescription
scoring_systemstringYesChoose DIPSS or DIPSS Plus scoring system
age_over_65stringYesAge greater than 65 years
wbc_over_25stringYesWhite blood cell count >25,000/μL (25 × 10⁹/L)
hemoglobin_under_10stringYesHemoglobin <10 g/dL (100 g/L)
peripheral_blast_1_or_morestringYesPeripheral blood blast ≥1%
constitutional_symptomsstringYesConstitutional symptoms (fever, night sweats, weight loss >10% in 6 months)
unfavorable_karyotypestringNoUnfavorable karyotype (complex karyotype or sole/two abnormalities including +8, -7/7q-, i(17q), -5/5q-, 12p-, inv(3), or 11q23 rearrangement) - Required for DIPSS Plus
platelets_under_100stringNoPlatelet count <100,000/μL (100 × 10⁹/L) - Required for DIPSS Plus
transfusion_dependentstringNoRed cell transfusion dependency - Required for DIPSS Plus

Score Interpretation & Guidance

RangeStageDescription
0–0Low riskLow risk category
1–2Intermediate-1 riskIntermediate-1 risk category
3–4Intermediate-2 riskIntermediate-2 risk category
5–8High riskHigh risk category

Evidence-Based References (EBM)

  • Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-8.
  • Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-7.

Related calculators